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Abstract
Background:  Sub optimal levels of compliance and persistence with bisphosphonates are
potentially compromising the reduction of post menopausal osteoporotic (PMO) fracture risk.
Methods: A structured literature search (1990–2006) was performed to identify primary research
studies evaluating the relationship between compliance and persistence with bisphosphonates and
post menopausal osteoporotic (PMO) fracture risk in clinical practice. Search criteria were:
bisphosphonates; osteoporosis/osteopenia in postmenopausal women; all types of fractures;
compliance and persistence.
Results: Only two retrospective studies using prescription databases have specifically evaluated
bisphosphonates.
A cohort study tracking 35,537 women reported that in those with a Medication Possession Ratio
(MPR) of ≥80% over 24 months the risk of fracture was lower than in those with an MPR of <80%
(8.5% v 10.7%, p < 0.001, Relative Risk Reduction (RRR) 21%). In women who persisted with
treatment (refill gap <30 days) the risk of fracture was also lower (7.7% v 10.3%, p < 0.001, RRR
29%).
A nested case control study reported that 12 months persistence (refill gap <50% previous
prescription (Rx) length) was associated with a 26% reduced risk of fracture (p < 0.05) and 24
months with a 32% reduced risk (p < 0.05).
Four other studies, not specific to bisphosphonates, reported that compliance ≥12 months
decreased fracture risk by ~25%.
Conclusion: Sub optimal compliance and persistence with bisphosphonates is not providing the
best possible protection against the risk of PMO fracture, however, more research is needed to
delineate this relationship in clinical practice.
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Background
Osteoporosis is characterised by low bone density, deteri-
oration of bone tissue and increased susceptibility to fra-
gility fractures [1] most commonly involving the hip,
vertebrae and distal radius [2].
International treatment guidelines recommend the use of
bisphosphonates as first line therapy, with the prime
objective of reducing the number of osteoporotic fractures
[3-6]. This class of products is now firmly established as
first line therapy with clinical trials having demonstrated
that treatment significantly reduces the incidence of both
vertebral and non vertebral fractures [4]. In placebo con-
trolled trials of alendronate and risedronate the relative
risk reduction (RRR) for vertebral fractures has been
reported as 50–60%, for hip fractures as 44–60% [4] and
for non vertebral fractures as 51% [7]. For ibandronate
users the risk of new vertebral fractures was reduced by up
to 62% (p = 0.0001) [8].
The effectiveness of treatments for chronic conditions is
generally compromised by sub optimal compliance and
persistence with treatment, particularly in asymptomatic
diseases [9-11] and a number of studies [12-15] have
reported poor levels of compliance and persistence with
commonly used drug therapies for osteoporosis including
bisphosphonates [16]. Approximately half of all patients
do not take bisphosphonates regularly [17] or continue
with treatment [18] for at least 12 months, with many dis-
continuing soon after initiation [19]. While less frequent
dosing regimens have significantly improved compliance
and persistence, adherence to treatment remains sub opti-
mal [20,21] and is likely to be compromising the benefits
of reduced fracture risk demonstrated in clinical trials.
The aim of this study was to identify primary research
studies evaluating the association between compliance
and persistence with bisphosphonates and the risk of
osteoporotic fracture in clinical practice, focusing on post-
menopausal women (>45 years) with osteoporosis or
osteopenia.
Methods
A structured search of bibliographic sources, including
MEDLINE®; EMBASE® (January 1990 – September 2006);
The Cochrane Library Databases (Issue 3, 2006, The
Cochrane Database of Systematic Reviews (CDSR), the
Database of Abstracts of Reviews of Effects (DARE), the
Central Health Technology Assessment (HTA) database;
and the NHS Economic Evaluation database (HEED), was
performed. The search was intended to identify primary
research studies evaluating the relationship between com-
pliance and persistence with bisphosphonates and post
menopausal osteoporotic fracture risk in clinical practice.
The search strategy devised in conjunction with the Royal
Society of Medicine Library in London was based on four
main criteria:
- Bisphosphonates as a broad term, as well as specific
bisphosphonates (e.g. ibandronate, alendronate, risedro-
nate, etidronate, clondronate, pamidronate, zoledronate
etc);
- All types of osteoporosis including osteopenia linked to
postmenopausal women. (Although all of the databases
searched had an indexing term to specifically describe
postmenopausal osteoporosis, for completeness, the
broader term for osteoporosis was also searched and com-
bined with terms to describe post menopausal and sub-
jects aged over 45 years);
- All types of fractures including hip, wrist, vertebral and
non vertebral;
- Compliance, non compliance, persistence, non persist-
ence, adherence and treatment refusal.
Indexing terms represented in the descriptor fields of ref-
erences and free-text terms appearing in the title or
abstract were included in the search. Free-text terms were
also searched for in the full text of Cochrane Reviews in
the CDSR. All study types were included (e.g. randomised
controlled trials, observational studies, etc.). The search
was restricted to female human subjects but papers not
gender specific were retained for review. Publications
reporting on the use of bisphosphonates for treating pain
as a result of bone metastases were excluded. The follow-
ing publication types were also excluded where possible:
letters, editorials, news items, case reports, historical arti-
cles and comments. EMBASE®  has a publication type
"note" and, as it was not clear how this is used in the data-
base, these were also included for review. A search of the
bibliographies of identified review articles and those
reporting on economic evaluations of bisphosphonates
was also made.
To understand the extent and direction of on-going
research, the structured literature review was supple-
mented by manual searching of journal supplements
reporting on relevant conference proceedings. A search
engine was also used to identify abstracts or posters from
conferences which had been posted on the internet by
31st October 2006.
All titles and abstracts retrieved were examined by two
reviewers to identify potentially relevant studies and cop-
ies of the full text were obtained. Relevant information
was summarised into a predefined grid: study reference,
country in which study performed, data source used,
study period, study population, interventions examined,BMC Musculoskeletal Disorders 2007, 8:97 http://www.biomedcentral.com/1471-2474/8/97
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duration of follow-up, outcome(s) measured as well as a
summary of key results and then evaluated.
In the studies reviewed, compliance had been measured
and reported as a Medication Possession Ratio (MPR %),
defined as the proportion of days within the follow-up
period for which patients had prescription cover. Persist-
ence had been measured as the time from initiation to dis-
continuation of treatment and reported as the number of
days from the index prescription to the end of the last pre-
scription issued in the follow-up period.
Results
After removal of duplicates, a total of 241 potentially rel-
evant references was identified from the searches; 193
from the combined search of MEDLINE® and EMBASE®
and 48 from the Cochrane Library databases (15 from
CDSR, 22 from CENTRAL and 11 from NHS HEED).
A review of all abstracts identified that the majority of
publications (235) had reported mainly on clinical trials
evaluating efficacy and safety of different bisphospho-
nates, observational studies separately examining fracture
risk, compliance and persistence, as well as health eco-
nomic evaluations of bisphosphonates. Only 6 studies
had specifically examined the association of compliance
and persistence with treatment on fracture rates.
Four studies were non specific to bisphosphonates
[13,18,22,23] and it was not possible to examine fracture
risk specifically relating to bisphosphonates. Women with
a diagnosis of osteoporosis and a prescription for either
etidronate, conjugated estrogens or alendronate had been
selected from a Canadian Health Insurance Database. The
minimum age in this cohort was 45 years and the mean
age 68 years. After adjustment for multiple covariates, the
RRR in those with an MPR ≥ 80% versus those with an
MPR <80% was 16% [13]. In women with osteoporosis
who regularly took hormone replacement therapy (HRT)
bisphosphonates or raloxifene [18] the risk of hip (OR =
0.38, p < 0.01) and vertebral fractures (OR = 0.60, p <
0.05) was significantly reduced. In those taking any type
of medication for osteoporosis, an MPR of <80% was
associated with an increased risk of fracture (17% 95%CI
9–25%) [22]. In another database study, a nested case
control design was used to compare the level of compli-
ance with medication in women ≥ 45 years who had expe-
rienced a fracture compared to those who had not. There
was an overall lower risk of fracture in those with an MPR
of ≥ 90% compared to those with an MPR of <30% (OR =
0.70, 95%CI 0.52–0.93) [23].
Only two bisphosphonate specific studies [24,25] evaluat-
ing daily and weekly bisphosphonate regimens have been
reported. The first, a cohort study in the USA [24], exam-
ined the risk of total, vertebral, non vertebral and oste-
oporotic hip fracture in 35,537 bisphosphonate naïve
women aged >45 years with a diagnosis of osteoporosis
and who had been prescribed daily or weekly regimens of
risedronate or alendronate.
In those with an MPR of ≥80% over 24 months (43%), the
relative risk of any fracture was 21% lower (p < 0.001)
compared to those with MPR <80%. The greatest risk
reduction was for hip and vertebral fractures (37%, p <
0.001). In women who persisted with treatment for 24
months (20%) the relative risk of any fracture was 29%
lower (p < 0.001) compared to those who did not persist
with treatment. Again the most significant decrease in risk
was for hip and vertebral fractures (44.5% and 40%
respectively, p < 0.001). The relationship between the full
range of MPR values (0–1.0) and the probability of frac-
ture indicated that the risk of fracture remained largely
unchanged for MPR values of up to approximately 50%,
declining with a shallow slope for MPR values between
50% and 75% and then more sharply between 75–100%.
In the subset of women with a diagnosis of post meno-
pausal osteoporosis (n = 6,391), the proportion who were
compliant (43%) or persistent (23%) was very similar to
that in the overall cohort. Compliance and persistence
with therapy was associated with a decrease in the risk of
all fractures (22% and 29% respectively, p < 0.001) as well
as in hip and vertebral fractures (46.6% and 35.5% respec-
tively, p < 0.001). Covariates that had been adjusted for in
these analyses were age, previous fracture history, baseline
estrogen and glucocorticosteroid use.
Several differences in baseline characteristics were
reported between compliant and non compliant patients
as well as between persistent and non persistent patients.
In both non compliant and non persistent groups there
were significantly more patients with a prior history of
diabetes (p < 0.001) or chronic renal insufficiency (p <
0.01) as well those who had previously taken estrogens,
estrogen combinations or oral glucocorticosteroids (p <
0.001).
The second study was performed in the Netherlands, with
data retrieved from the PHARMO Record Linkage System.
A nested case control study design evaluated the associa-
tion between persistent bisphosphonate use and the risk
of hospitalisation for osteoporotic fractures [25]. A cohort
of 14,760 bisphosphonate naive women initiated on
alendronate, risedronate or etidronate was retrieved.
From this cohort 541 (3.7%) cases were identified who
had been hospitalised for an osteoporotic fracture after
commencing treatment. The level of persistence with
bisphosphonates in this group was compared to controls
(n = 5,410) who had not been hospitalised for an oste-BMC Musculoskeletal Disorders 2007, 8:97 http://www.biomedcentral.com/1471-2474/8/97
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oporotic fracture. One year persistent use of bisphospho-
nates was associated with a 26% lowered risk of fracture
(OR 0.74, p < 0.05) and two years persistent use was asso-
ciated with a 32% lowered risk (OR 0.68, p < 0.05). Cov-
ariates that had been adjusted for in these analyses were
age, year of fracture, previous osteoporotic fracture and
use of analgesics or antidepressants between the index
date and fracture date.
In this study, cases were significantly older than the con-
trol population with a higher proportion being over 60
years (p < 0.0001). Cases also included fewer users of
weekly bisphosphonates. A greater number had also expe-
rienced a previous fracture (p = 0.002) or had taken HRT
more frequently (p = 0.045) in the one year period before
the index date.
The data from only one abstract [28] has been fully
reported in a peer reviewed journal [26] the others were
preliminary findings [27,29-34]. The results however,
endorsed the findings from the published studies, report-
ing an approximate 25% lower risk of fracture in patients
who were compliant or persistent with bisphosphonates
for at least 2 years [30,31]. The risk of hospitalisation for
osteoporotic fracture was also significantly lower, [28] as
was the length of hospital stay [33] and associated health-
care expenditure [32].
Discussion
Currently available evidence on the association between
compliance and persistence with bisphosphonates and
fracture risk in clinical practice is limited to only two stud-
ies. However, both have reported that if bisphosphonates
are taken regularly and for at least a year the risk of expe-
riencing a fracture is reduced by approximately 25%. They
have therefore started to delineate the important relation-
ship between the level of compliance and persistence and
the probability of a PMO related fracture in clinical prac-
tice. The results presented in preliminary reports examin-
ing daily and weekly bisphosphonates support the above
findings, reporting that higher levels of compliance
reduce the risk of fracture [27-34] with a consistently high
level of compliance (MPR ≥ 90%) being required for an
optimal protective effect. [30].
Studies examining groups of treatments for osteoporosis,
including etidronate and conjugated estrogens [13], HRT,
bisphosphonates and raloxifene [18], all osteoporosis
medication [22,23] have also reported the positive rela-
tionship between higher levels of compliance with oste-
oporosis therapy and fracture risk. Most of the studies
have used somewhat arbitrary thresholds to define com-
pliance and persistence (e.g. 80% or 90% MPR) and in
future a linear analytical model may be more useful in
determining a clinically relevant relationship between
fracture risk and different levels of compliance and per-
sistence.
From a public health perspective, based on data from the
USA study, an estimate of the likely benefit associated
with improving compliance and persistence with bisphos-
phonates would be a reduction of 2,200 fractures per
100,000 over two years [24]. From the results presented in
the study from the Netherlands, if the proportion of
women who persist with treatment for at least a year
increased by 15%, then there would be 400 fewer fractures
per 100,000 per year [25].
The studies reviewed highlight that compliance and per-
sistence levels with bisphosphonates are sub-optimal
[17,18] with many discontinuing treatment soon after
therapy initiation [19]. A diagnosis of osteoporosis does
not appear to improve compliance with bisphosphonates
[24] but women with a previous history of fracture are
more persistent with treatment [18]. Clinical studies have
demonstrated that a number of support activities can
enhance compliance and persistence including the regular
provision of patient information, repeat prescription
reminder services as well as nurse counseling and support
programmes [35]. However, there does not appear to be a
systematic or sustained implementation of such activities
in clinical practice and preliminary evidence indicates that
take-up is low (~10%) [36].
The two retrospective studies of bisphosphonates will
have some inherent data and analytical limitations as they
were based on observational data sources. Assumptions
are likely to have been made on the length of a prescrip-
tion and the issuing of a prescription is only an indirect
measure of medication usage and does not necessarily
imply that the drug was taken in the frequency or manner
expected. Therefore compliance and persistence levels
could have been overestimated. In addition recording of
osteoporotic fractures may not have been comprehensive,
particularly if a patient had not sought medical care. Sim-
ilarly, fragility fractures recorded as non traumatic may
not have been validated so any count may have included
some trauma fractures.
Nonetheless observational databases have been able to
provide reliable estimates of patient use of medications
[37] and, as the two studies examined were comparative,
any bias as a result of inconsistencies in data recording
would apply equally to each of the cohorts. Importantly,
these resources provide access to data on real life clinical
practice in large representative samples of individuals and
represent a practical alternative to performing naturalistic
studies.BMC Musculoskeletal Disorders 2007, 8:97 http://www.biomedcentral.com/1471-2474/8/97
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Conclusion
While the existing evidence is limited it does suggest that
improving compliance and persistence with bisphospho-
nates will reduce the risk of fracture in clinical practice. In
countries such as the UK where bisphosphonate regimens
are the main stay of treatment [38] this could be examined
using varying compliance and persistence metrics as well
as a combined metric of compliance and persistence.
Additionally, the protective therapeutic time window fol-
lowing a stop or interruption in treatment also needs be
investigated.
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